Winston Pharmaceuticals, Inc. (WPHM.OB) Announces Positive Top-line Results of Phase I Clinical Trial of Civamide Patch
2/9/2009 12:40:26 PM
VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-01, a Phase I clinical trial evaluating the tolerability and pharmacokinetic profile of two concentrations of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator. The study successfully demonstrated the tolerability of the two concentrations tested for continuous application to the skin for a period of one week. Additionally, there was no systemic absorption of civamide detected in any patients, supporting its local use for the topical treatment of post-herpetic neuralgia.
comments powered by